Anti-Human IgM µ-Chain Specific (Clone HB57) – Purified in vivo GOLD™ Functional Grade

Clone HB57 is a mouse monoclonal antibody specific for the human IgM µ-chain, and its most common in vivo applications in mice are related to the study of immune responses to human immunoglobulins, detection and depletion of human B cells, and modeling drug-induced immune reactions in humanized or transgenic mice expressing human IgM or immune system components.

Key in vivo applications of clone HB57 in mice include:

• Detection and Quantification of Human IgM: Used to monitor human IgM levels in mice, especially in xenograft or humanized mouse models reconstituted with human immune cells.
• Functional Depletion or Blockade of Human IgM+ B Cells: Employed in experiments aiming to deplete human IgM-expressing B cells or block their activity, to investigate the role of these cells in immune responses or disease models (for example, autoimmunity, transplantation, or infection studies).
• Mechanistic Studies of Human Immune Interactions: Applied in in vivo models to dissect the roles of human IgM in processes such as complement activation, immune complex formation, and modulation of downstream immunological pathways.
• Assessment of Hypersensitivity and Drug Reactions: Utilized in transgenic mice (such as those expressing human HLA alleles or immunoglobulins) to model and study immune-mediated adverse reactions to drugs, by tracking or manipulating human IgM responses.

Supporting details:

• The antibody is often used at low endotoxin and high purity levels to allow safe and consistent in vivo studies.
• Functional grade versions are selected for animal work to limit immunogenic contaminants.
• Clone HB57’s specificity for the human µ-chain allows it to target only human IgM without cross-reactivity to mouse immunoglobulins.
• Its in vivo use is often in the context of chimeric or humanized mouse strains that provide a suitable environment for human immune components.

No direct evidence in the retrieved results suggests a use outside of the above applications. Most research reporting on clone HB57 centers on its ability to recognize and functionally modulate human IgM in the context of mouse models engineered for human immune study. If further specificity or a niche application is needed, targeted queries or manufacturer datasheets should be consulted for precise experimental protocols.

The antibody HB57 is an anti-human IgM µ-chain-specific monoclonal antibody commonly used in immunology research. In the literature, HB57 is often used in combination with several other antibodies or detection reagents, depending on the application.

Commonly used antibodies or proteins paired with HB57 include:

• Anti-IgG antibodies: In experiments where multiple immunoglobulin isotypes (e.g., IgG, IgA) are analyzed simultaneously, anti-IgG antibodies are used alongside HB57 to distinguish IgM from other antibody classes.
• Secondary antibodies: Since HB57 is often raised in mouse, anti-mouse IgG secondary antibodies (conjugated to enzymes like HRP or fluorescent tags) are typically used for detection in assays such as ELISA and flow cytometry.
• Cellular markers: For immunophenotyping or cell sorting, antibodies against cell surface markers (e.g., CD19 for B cells) are frequently combined with HB57 to identify IgM-expressing B cell populations.
• Other immunoglobulin isotype-specific antibodies: These may include anti-IgD, anti-IgA, or anti-IgE to comprehensively characterize antibody repertoires in mixture with HB57.

In addition to these, laboratories may use detection reagents like protein G or protein L for broader immunoglobulin capture, or combine HB57 with markers specific for particular cellular subsets depending on the experimental question.

In summary, HB57 is most commonly used with:

• Anti-IgG and other isotype-specific antibodies
• Secondary anti-mouse IgG antibodies
• Cell surface markers such as CD19

Reference to these combinations can be found in typical protocols and product datasheets for HB57, as well as in published immunology research.

The clone HB57, often referenced in scientific literature as HB57-dex, is primarily associated with its role in B-cell receptor (BCR) stimulation. Here are the key findings from its citations:

1. BCR Stimulation and Telomerase Activity: HB57-dex is used as a multivalent BCR ligand to study the effect of BCR stimulation on telomerase activity in B-cell chronic lymphocytic leukemia (B-CLL) cells. It has been observed that HB57-dex increases telomerase activity and promotes cell survival and proliferation preferentially in U-CLL cases, which are characterized by unmutated IGHV genes.

2. Differential Response in U-CLL and M-CLL: In comparison to M-CLL (mutated IGHV genes), U-CLL clones exhibit a positive trend in responsiveness to HB57-dex, with increased Ca2+ flux leading to higher S phase entry and elevated telomerase activity. However, M-CLL cases do not show significant proliferation or telomerase activity in response to HB57-dex.

3. Signaling Pathways and Inhibitors: The PI3K/Akt inhibitor LY294002 blocks HB57-dex-induced telomerase activation, indicating that these pathways are crucial for BCR-mediated effects on telomerase activity.

These findings highlight the role of HB57-dex in elucidating BCR functions and their implications for B-CLL pathology. There are no direct associations with other scientific concepts like HLA-B57 in the context of HB57 citations. HLA-B57 refers to a different topic related to HIV control and is not directly linked to HB57-dex.

Dosing regimens for clone HB57 in mouse models are not standardized and can vary significantly based on the specific research objectives and mouse models being used. Unfortunately, the available information does not provide specific details about the actual dosing protocols, frequencies, or concentrations employed for this particular antibody clone across different experimental systems.

The lack of standardization in dosing regimens for clone HB57 reflects a broader challenge in antibody-based research using mouse models, where researchers must optimize protocols based on several factors including the biological endpoint being measured, the particular strain of mouse, the duration of the study, and the specific mechanisms being investigated. Without established guidelines, individual laboratories develop their own dosing strategies tailored to their experimental needs.

For researchers planning to use clone HB57, this means that dosing parameters would need to be empirically determined or adapted from similar antibody studies in comparable model systems, taking into account factors such as the antibody's half-life, the target antigen expression levels, and the desired degree of immune modulation or depletion.